Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

科前生物:拟与华中农大签订合作研发协议 有助于增加公司产品储备
Pre-science biology: the proposed cooperative R & D agreement with Huazhong Agricultural University will help to increase the company's product reserve.

發佈易 ·  {{timeTz}}

发布易2月15日 - 科前生物(688526)公告称,公司经与华中农大竞争性谈判,取得了犬细小病毒VP2蛋白重组犬瘟热病毒活疫苗,狂犬病灭活疫苗(SAD-dOG株),狂犬病病毒G蛋白ELISA抗体检测试剂盒等三个项目的合作研发,现拟与华中农大签订联合开发协议书,公司就以上三个研发项目一共需向华中农大支付340万元。合作研发项目产生的技术成果及知识产权归公司及华中农大共同所有。通过合作研发,可以增加公司产品储备,提升公司市场竞争力。

Release February 15-pre-science biology (688526) announced that through competitive negotiations with Huazhong Agricultural University, the company has obtained three projects: recombinant live canine distemper virus vaccine with VP2 protein of canine parvovirus, inactivated rabies vaccine (SAD-dOG strain), rabies virus G protein ELISA antibody detection kit, and now plans to sign a joint development agreement with Huazhong Agricultural University. The company needs to pay a total of 3.4 million yuan to Huazhong Agricultural University for the above three R & D projects. The technical achievements and intellectual property rights produced by the cooperative R & D project are jointly owned by the company and Huazhong Agricultural University. Through cooperative research and development, we can increase the company's product reserve and enhance the company's market competitiveness.

This page is machine-translated. Moomoo tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.